Drug Type Monoclonal antibody |
Synonyms- |
Target |
Action inhibitors |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Melanoma | Phase 1 | France | 08 Nov 2018 | |
| Melanoma | Phase 1 | Spain | 08 Nov 2018 | |
| Metastatic melanoma | Phase 1 | France | 08 Nov 2018 | |
| Metastatic melanoma | Phase 1 | Spain | 08 Nov 2018 |
Phase 1 | Refractory Melanoma ICOS | Ki-67 | ALC | - | bihzqyochq(yoygfnwqov) = dose-dependent increase of ALC and CD4+ and CD8+ T cells lidobxthuk (dswonklohx ) View more | - | 02 Nov 2023 |






